3 European RW, chart review studies in people with type 2 #diabetes managed using basal bolus insulin therapy each concluded that HbA1c was significantly reduced after changing to use of flash glucose monitoring for 3–6 months in a real-world setting. http
RT @drpatrickholmes: In people with #type2diabetes on basal bolus insulin therapy. ⬇️HbA1c 0.8-0.9% after changing to use of flash glucose…
RT @Aldibbiat: Flash is a powerful tool, the effect on HbA1C reduction (~1%) is on bar with other therapy agents, but here there is a great…
Flash is a powerful tool, the effect on HbA1C reduction (~1%) is on bar with other therapy agents, but here there is a great benefit on Quality of Life
RT @MarisaAmaya13: El sistema flash se creó en un principio para personas adultas con diabetes tipo 1 y tipo 2. Así que ojalá en breve poda…
RT @CristobMorales: https://t.co/vMTQgnKcqi “3 European realworld studies in people with t2 diabetes with basal bolus insulin therapy concl…
RT @MarisaAmaya13: El sistema flash se creó en un principio para personas adultas con diabetes tipo 1 y tipo 2. Así que ojalá en breve poda…
RT @MarisaAmaya13: El sistema flash se creó en un principio para personas adultas con diabetes tipo 1 y tipo 2. Así que ojalá en breve poda…
RT @MarisaAmaya13: El sistema flash se creó en un principio para personas adultas con diabetes tipo 1 y tipo 2. Así que ojalá en breve poda…
RT @MarisaAmaya13: El sistema flash se creó en un principio para personas adultas con diabetes tipo 1 y tipo 2. Así que ojalá en breve poda…
RT @CristobMorales: https://t.co/vMTQgnKcqi “3 European realworld studies in people with t2 diabetes with basal bolus insulin therapy concl…
RT @CristobMorales: https://t.co/vMTQgnKcqi “3 European realworld studies in people with t2 diabetes with basal bolus insulin therapy concl…
El sistema flash se creó en un principio para personas adultas con diabetes tipo 1 y tipo 2. Así que ojalá en breve podamos financiarlo a todas las personas con DM y régimen insulínico basal/bolo.
RT @CristobMorales: https://t.co/vMTQgnKcqi “3 European realworld studies in people with t2 diabetes with basal bolus insulin therapy concl…
RT @CristobMorales: https://t.co/vMTQgnKcqi “3 European realworld studies in people with t2 diabetes with basal bolus insulin therapy concl…
RT @CristobMorales: https://t.co/vMTQgnKcqi “3 European realworld studies in people with t2 diabetes with basal bolus insulin therapy concl…
RT @CristobMorales: https://t.co/vMTQgnKcqi “3 European realworld studies in people with t2 diabetes with basal bolus insulin therapy concl…
RT @jescribano19: No te digo que no, pero pero resultados muy influenciados por la población con muy mal control (>9% o >75). https://t.co/…
No te digo que no, pero pero resultados muy influenciados por la población con muy mal control (>9% o >75).
RT @CristobMorales: https://t.co/vMTQgnKcqi “3 European realworld studies in people with t2 diabetes with basal bolus insulin therapy concl…
RT @CristobMorales: https://t.co/vMTQgnKcqi “3 European realworld studies in people with t2 diabetes with basal bolus insulin therapy concl…
RT @CristobMorales: https://t.co/vMTQgnKcqi “3 European realworld studies in people with t2 diabetes with basal bolus insulin therapy concl…
https://t.co/vMTQgnKcqi “3 European realworld studies in people with t2 diabetes with basal bolus insulin therapy concluded that A1c was significantly reduced after changing to use of flash glucose monitoring“. Es tiempo de financiación FSL en DM2 con MDI?
RT @drpatrickholmes: In people with #type2diabetes on basal bolus insulin therapy. ⬇️HbA1c 0.8-0.9% after changing to use of flash glucose…
RT @drpatrickholmes: In people with #type2diabetes on basal bolus insulin therapy. ⬇️HbA1c 0.8-0.9% after changing to use of flash glucose…
RT @drpatrickholmes: In people with #type2diabetes on basal bolus insulin therapy. ⬇️HbA1c 0.8-0.9% after changing to use of flash glucose…
Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes https://t.co/vwJNn4Nf9u
RT @drpatrickholmes: In people with #type2diabetes on basal bolus insulin therapy. ⬇️HbA1c 0.8-0.9% after changing to use of flash glucose…
RT @drpatrickholmes: In people with #type2diabetes on basal bolus insulin therapy. ⬇️HbA1c 0.8-0.9% after changing to use of flash glucose…
RT @drpatrickholmes: In people with #type2diabetes on basal bolus insulin therapy. ⬇️HbA1c 0.8-0.9% after changing to use of flash glucose…
RT @drpatrickholmes: In people with #type2diabetes on basal bolus insulin therapy. ⬇️HbA1c 0.8-0.9% after changing to use of flash glucose…
RT @drpatrickholmes: In people with #type2diabetes on basal bolus insulin therapy. ⬇️HbA1c 0.8-0.9% after changing to use of flash glucose…
RT @drpatrickholmes: In people with #type2diabetes on basal bolus insulin therapy. ⬇️HbA1c 0.8-0.9% after changing to use of flash glucose…
RT @drpatrickholmes: In people with #type2diabetes on basal bolus insulin therapy. ⬇️HbA1c 0.8-0.9% after changing to use of flash glucose…
In people with #type2diabetes on basal bolus insulin therapy. ⬇️HbA1c 0.8-0.9% after changing to use of flash glucose monitoring for 3–6 months in a real-world setting @kamleshkhunti @AmarPut @DSNforumUK @HPILLminster @WilmotEmma @ShafieMSK https://t.co